No Fungus Action

New Phase II query grades of HUMIRA(reg) (adalimumab) within patients next to pleasant to austere hardened plaque psoriasis spectacle that patients achieve imperative and unceasing recovery in virus movement and competence of existence complete 24 weeks of conduct, with nearly partially of patients experiencing a 90 percent improvement in disease activity. These iq be presented today at the American Academy of Dermatology (AAD) summer reunion in New York City.

Psoriasis be a chronic, non-contagious husk disease characterized via extremely barren, peeling and broken skin; skin misery; and patch of red, raise skin lasting through “plaques.” This beyond the pallid disease, which at the moment hold no treatment, affect convoluted than 4.5 million citizens in the United States.

In the study, 64 percent of patients taking HUMIRA 40 mg all other week (eow) achieved at smallest a 75 percent improvement in disease amount and firmness after 24 weeks. Furthermore, 42 percent of patients taking HUMIRA 40 mg eow knowing at least a 90 percent improvement in their disease.

Patients also record significant improvement in quality of life measures: after 24 weeks, 40 percent of patients report their quality of life be “not at all” mannered by their psoriasis, as measured by the Dermatology Life Quality Index (DLQI) — a index of patient-reported effect in dermatology.

“Psoriasis can be a vital disease with oversize quality of life implication, as a result it is important that we coat to hope out influential treatment examination in desire of patients,” said head investigator Kenneth Gordon, M.D., Associate Professor of Medicine, Loyola University, Chicago Stritch School of Medicine. “In this study, patients by the side of HUMIRA experienced a clinically significant answer, added to to quality of life improvements. Even more encouraging is the digit of patients in the try-out who achieved 90 percent improvement in their disease — an important measure that go elapsed what is routinely highlighted in clinical trial.” Study Design This double-blind study measured the price and tolerability of HUMIRA after a meticulous of 24 weeks of treatment. It was the prolongation of a 12-week trial where on earth participant (n148) with a diagnosis of moderate to severe chronic plaque psoriasis for at least one year and an affected article shallow locality of 5 percent were randomized to receive HUMIRA or placebo administered by subcutaneous shot (under the skin).

The results for the gap 12 weeks of psychotherapy were reported at the AAD meeting in February 2004.

Patients completing the first 12 weeks of the trial (n137) were eligible to continue. Patients who have be approval HUMIRA 40 mg eow, and patients receiving HUMIRA 40 mg weekly, continued with treatment at alike dose for the supplementary 12 weeks. Beginning at week 12, patients in the placebo arm received 12 weeks of therapy, with an opening dose of 80 mg of HUMIRA follow by 40 mg eow formation at week 13. Patients and physician remain blind to dose until week 24, at which spike patients were clash uphill to.

Measuring Efficacy and Tolerability The former efficacy endpoint was the percentage of patients achieve at least a 75 percent diminution in disease activity after 24 weeks of treatment as measured by the Psoriasis Area and Severity Index Score (PASI 75) compare to the baseline plus point at week 0. PASI measures the extent and severity of psoriasis. Results at 24 weeks show that 64 percent of patients receiving HUMIRA 40 mg eow achieved PASI 75. Seventy-two percent of patients who received HUMIRA 40 mg weekly achieved PASI 75. Results also explain that 55 percent of the patients who were switch from placebo to the 40 mg eow regimen beginning at week 12 achieved PASI 75 after 12 weeks of therapy. These data be analogous to the results of patients receiving HUMIRA 40 mg eow in the first 12 weeks of the initial trial, where response were see as precipitate as the first week of therapy.

The percentage of patients achieving PASI 90 - a width that correlate to at least a 90 percent reduction in disease activity - also was significant. Results at 24 weeks show that 42 percent of patients receiving HUMIRA 40 mg eow and 62 percent of patients receiving HUMIRA 40 mg weekly achieved PASI 90. For those patients who begin taking HUMIRA 40 mg eow at week 12, 32 percent achieved PASI 90, mark a significant improvement in disease activity.

Disease activity was also measured by the Physician’s Global Assessment, a measurement bradawl nearly foreign by physicians to consider severity of disease. Results showed that 45 percent of patients receiving placebo/40 mg eow (placebo for 12 weeks followed by HUMIRA 80 mg subsequent 40 mg eow) were “clear” (representing no signs of psoriasis) or “almost clear” after 12 weeks of therapy. At 24 weeks, 64 percent of patients receiving HUMIRA 40 mg eow were “clear” or “almost clear” of their psoriasis, as were 72 percent of patients taking HUMIRA 40 mg weekly.

There were no new safekeeping warmth in the psoriasis population compared with those observed in the rheumatoid arthritis population. Adverse measures occurring in 5 percent of patients incorporated headache, injection place pain, nasopharyngitis, triglyceride increase, digestive disorders, skin papilloma, nausea, nonspecific upper respiratory pollution and fatigue.

Quality of Life Results Patients receiving any dose of HUMIRA reported greatly greater improvements in DLQI at 12 weeks than those receiving placebo, and those improvements continued over 24 weeks.

At 24 weeks, 40 percent of patients receiving HUMIRA 40 mg eow reported a DLQI of “0″, goods they were “not at all” affected by their psoriasis. Nearly 55 percent of patients on weekly dosing and 26 percent of those on placebo/40 mg eow reported they were “not at all” affected by their psoriasis after receiving HUMIRA.

The DLQI index ranges from 0-30, with 30 representing the worst quality of life for psoriasis patients. A show vacillation of -5 imply a minimal clinically important difference in DLQI.

At baseline, the mean DLQI was relating 12.2 and 13.6, and patients in all in-group experienced better quality of life at the closing of treatment. Patients taking placebo/HUMIRA 40 mg eow experienced a mean change in DLQI of -8.2 after 24 weeks. Patients receiving HUMIRA 40 mg eow showed a mean DLQI change of -10.2 at week 24. Those taking HUMIRA 40 mg weekly experienced a mean change of -11.6 after 24 weeks.

“We are thrilled to see patients here study undertake improvements in the corporal and pouring effects of psoriasis through treatment with HUMIRA and are impelled by the burgeoning results we have seen so far in our psoriasis trials,” said Jim Lefkowith, M.D., divisional vice president, Immunology Development, Abbott Laboratories.

About Psoriasis According to a 2001 hypothesis opinion poll conduct by the National Psoriasis Foundation, 75 percent of people with moderate to severe psoriasis word that their disease has a moderate to elder impact on their commonplace live, with 26 percent of people altering their standard daytime after day happenings and 21 percent cessation their normal daily activities.

HUMIRA is not stand for for treatment of psoriasis. Clinical trials are going ahead evaluate the resting of HUMIRA in psoriasis and other autoimmune disease.

Important Safety Information Cases of tuberculosis (TB), experience and again disseminated or over pulmonary at clinical performance, have been observed in patients receiving HUMIRA. Serious infection and sepsis, with fatalities, have been reported with the take plus of of TNF-blocking agents, including HUMIRA. Many of these infections take place in patients on concomitant immunosuppressive therapy that in postscript to their underlying disease could bias them to infections. Other forward opportunistic fungal infections have also been observed in patients luxury with TNF-blocking agents, including HUMIRA.

TNF-blocking agents, including HUMIRA, have been associated in at death`s door out cases with exacerbation of demyelinating disease. Lymphoma has been observed in patients treated with TNF-blocking agents. The best recurring adverse events seen in the placebo-controlled clinical trials in rheumatoid arthritis (HUMIRA vs. placebo) were injection site spontaneous effect (20 percent vs. 14 percent), upper respiratory infection (17 percent vs. 13 percent), injection site pain (12 percent vs. 12 percent), headache (12 percent vs. 8 percent), over-hasty (12 percent vs. 6 percent) and sinusitis (11 percent vs. 9 percent). Discontinuations in the red to adverse events were 7 percent for HUMIRA and 4 percent for placebo. As with any treatment program, the benefits and hazard of HUMIRA should be cooperatively considered sooner initiate therapy.

About HUMIRA HUMIRA is the lone fully human monoclonal antibody standard by the U.S. Food and Drug Administration (FDA) for reducing the signs and symptom and inhibit the evolution of structural jerk in adults with relatively to stringently involved RA who have had laughable response to one or more disease modify antirheumatic drugs (DMARDs).

HUMIRA can be used alone or in mixture with methotrexate (MTX) or other DMARDs. The efficacy and safety of HUMIRA have been studied in 23 clinical trials and in more than 2,300 patients, making it the most-studied TNF antagonist for RA at the time of regulatory submission. HUMIRA was approved by the FDA on December 31, 2002.

The interim analysis was specified in the clinical trial protocol to be a foil for the efficacy of pafuramidine compare to pentamidine, as all correct as the safety and tolerability of pafuramidine.

HUMIRA is the first fully human monoclonal antibody approved in Europe for RA, and the first tumor necrosis factor alpha (TNF-) antagonist approved with an proposition for use with methotrexate or as monotherapy. In April 2004, the European Medicines Evaluation Agency (EMEA) granted a cheery opinion for a HUMIRA gluey label new site for reducing the rate of progression of organized damage as measured by X-ray and doing marvellously physical drive in adults with RA.

To date, HUMIRA has been approved in 51 country and prescribed to more than 75,000 patients all-embracing persecute from rheumatoid arthritis.

The web-based program, which the researchers telephone “Puff City,” try to inculcate the teenagers cheerful behaviors to help them optimal hold power over and done with their asthma. It confident by the cross of three central behaviors: controller medication adherence, rescue inhaler availability and smoke cessation or running down.

Abbott particular discriminatory worldwide rights to HUMIRA, including guilt for clinical foundation, work, mart and marketing. Abbott will nuptials album all revenues for HUMIRA, and CAT will receive a sovereigns payment base on HUMIRA sales.

Abbott’s Commitment to Immunology Abbott is determined on the bringing to restrained and development of anti-government treatment for immunologic diseases. The Abbott Bioresearch Center, found in 1989 in Worcester, Mass., United States, is a world-class discovery and primary research facility committed to finding new treatments for autoimmune diseases. More information more or smaller quantity Abbott Immunology and HUMIRA, including full prescribe information, is accessible on the Web site ampills.com and ampills.com, or in the United States by calling Abbott Medical Information at 1-800-633-9110.

About Abbott Abbott Laboratories is a intercontinental, broad-based strength thoroughness enterprise keen to the discovery, development, misrepresentation and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employ more than 55,000 people and marketplace its products in more than 130 countries.